Can better support keep people on HIV prevention? massive malawi trial aims to find out
NCT ID NCT07221747
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This large study in Malawi will test whether extra support—like better communication with providers, peer counselors, and earlier clinic hours—helps people at high risk for HIV stay on their prevention medication. It includes both daily pills and a new long-acting injectable. Nearly 10,000 participants will be followed to see if these strategies improve continuation of PrEP.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Long-acting injectable cabotegravir and oral PrEP (tenofovir-based)
- What this could lead to
- If successful, this could show practical ways to help more people stay on HIV prevention, reducing new infections in high-risk groups.
- What could go wrong
- This is a behavioral study, not testing a new drug. Results may not apply outside Malawi, and adherence strategies may not work as well in other settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG-ACTING INJECTABLE CABOTEGRAVIR FOR PREP are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Community Health Science Unit
RECRUITINGLilongwe, Malawi
More trials for these conditions
Other studies related to the condition(s) this trial covers.